Bone Marrow Stem Cell Therapy

Bone marrow aspirate concentrate (BMAC) is an autologous regenerative therapy that utilizes bone marrow–derived cellular components to support tissue repair in select musculoskeletal and degenerative conditions.

At Alypos, BMAC is considered only when clinically appropriate and delivered with image guidance and individualized planning rather than protocol-based application.

Experience Matters

Bone marrow aspiration and concentrate preparation have become increasingly standardized through commercial kits.

Dr. Bernhardt instead uses a physician-controlled protocol developed from years of experience in image-guided interventional pain medicine and regenerative procedures.

Harvest technique, preparation variables, and injection strategy are individualized rather than delegated to a predetermined kit-based workflow.

Diagnosis, patient selection, harvest technique, processing, concentration, image-guided placement, and post-procedure rehabilitation all influence the final result.

At Alypos, these elements are considered together rather than as independent steps.

Procedural Precision

Bone marrow aspirate concentrate (BMAC) procedures involve minimally invasive marrow aspiration followed by controlled processing and targeted delivery to the affected anatomical structure.

Image guidance is used throughout the procedure to optimize accuracy and procedural safety.

At Alypos, each procedure is performed under high-resolution ultrasound guidance to allow precise placement of regenerative biologic material at the specific structure responsible for pain or dysfunction.

Marrow aspiration is performed using a multi-site, low-volume technique designed to optimize cellular yield and maintain aspirate quality prior to processing.

Large-volume aspiration from a single location increases dilution with peripheral blood.

A low-volume, multi-site technique is intended to maximize marrow quality before processing.

Treatment planning and injection technique are individualized based on patient anatomy, imaging findings, and clinical objectives rather than applied through standardized protocols.

Procedural planning integrates clinical examination with diagnostic imaging to ensure biologic therapy is delivered to a clearly defined anatomical target.

This approach prioritizes precision and appropriate case selection rather than protocol-driven treatment.

Preparation Environment

Unlike many office-based procedures performed directly on a countertop or procedure tray, biologic preparation at Alypos is performed within a dedicated Class II medical airflow hood designed to provide a controlled preparation environment.

Bone marrow aspiration is only the first step.

How the sample is collected, processed, concentrated, and handled before reinjection can meaningfully influence the biologic composition being delivered.

For that reason, Alypos uses physician-directed preparation rather than relying exclusively on fixed commercial kits.

Preparation is tailored to the clinical situation, including how samples are handled, processed, and timed to support appropriate tissue response.

This preparation environment reflects a procedural standard beyond what is typically found in routine office-based injection practices.

Bone marrow aspirate concentrate (BMAC) therapy at Alypos Regenerative Pain & Wellness in Southlake, Texas is performed as part of a physician-directed regenerative treatment program for selected musculoskeletal conditions.

When BMAC May Be Considered

BMAC may be considered in select orthopedic or degenerative conditions where structural tissue compromise is present and conservative measures have failed. In cases where bone marrow-derived therapy is not ideal, alternative autologous cellular sources may occasionally be evaluated.

Alternative Cellular Sources

In certain clinical scenarios, alternative autologous cellular sources may be considered when bone marrow–derived therapy is not optimal or when additional biologic support is warranted.

Adipose-Derived Cellular Therapy

In selected cases, minimally invasive harvest and processing of adipose tissue may be utilized for specific musculoskeletal or soft-tissue applications following detailed clinical evaluation.

Risks and Limitations

As with any medical procedure, BMAC carries risks and limitations that are reviewed during consultation. Response varies among individuals, and no specific outcome can be guaranteed.

BMAC at Alypos is integrated within a broader musculoskeletal and regenerative framework. Decisions regarding its use reflect clinical judgment, experience, and patient-specific factors rather than trends or standardized protocols.

Because biologic therapies are not appropriate for every condition, careful patient evaluation and individualized treatment planning remain central to the Alypos approach.

Alypos Approach to "Stem Cell" therapy

The biologic is only one component of treatment.

Precision diagnosis, physician-directed preparation, and accurate image-guided delivery are what determine whether that biologic has the best opportunity to help.

Frequently Asked Questions About Stem Cells

Do products marketed as “stem cell therapy” always contain meaningful numbers of stem cells?

No. That should never be assumed.

The term “stem cell therapy” is frequently used as a broad marketing label for biologic products that may differ substantially in their source, processing, composition, regulatory status, and supporting evidence.

Some websites list mesenchymal stem cells, progenitor cells, fibroblasts, endothelial cells, growth factors, cytokines, extracellular vesicles, and other biologic components. Listing cells that may exist in the original tissue, however, is not the same as demonstrating that those cells are present in the final injectable product, remain viable after processing and storage, or exist in clinically meaningful numbers.

A long list of scientific terms is not a substitute for direct characterization of the product actually being injected.

Are umbilical cord and birth-tissue products the same as bone marrow aspirate concentrate?

No. They are fundamentally different biologic products.

Bone marrow aspirate concentrate, or BMAC, is prepared from your own bone marrow during the same procedure. The treating physician controls the harvest, preparation, concentration, and image-guided delivery.

Umbilical cord and other birth-tissue products are donor-derived and manufactured elsewhere before being shipped to the treating clinic. Their contents depend on the source tissue, manufacturing process, storage conditions, thawing protocol, and testing of the final product.

They should not be considered interchangeable simply because both may be promoted using the terms “stem cells” or “regenerative medicine.”

What should I ask before receiving a donor-derived “stem cell” product?

Before any donor-derived biologic is injected, the treating physician should be able to answer several basic questions clearly:

What exactly is the final injectable product?
Who manufactured it, and where was it manufactured?
Was the final product directly tested for the cells being claimed?
How many of those cells remain viable after storage and thawing?
Is there a validated potency assay?
What published evidence supports this specific product for my condition?
Is the product FDA-approved for the proposed use?

If the manufacturer cannot be identified, the contents cannot be clearly explained, or the claims are based primarily on what may have existed in the original tissue rather than testing of the final product, patients should pause before proceeding.

Why does Alypos avoid exaggerated “stem cell” claims?

Because regenerative medicine deserves scientific precision rather than promotional terminology.

At Alypos, treatments are described by what they actually are, such as platelet-rich plasma or bone marrow aspirate concentrate. We do not use long lists of possible cell types to imply that every listed cell has been confirmed in meaningful quantities or proven to produce a specific clinical outcome.

Treatment begins with identifying what is actually causing your symptoms, determining whether regenerative treatment is appropriate, and selecting the most defensible option for your condition.

If we cannot clearly explain what is being injected, where it came from, and why it is appropriate, we will not recommend it.